Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
186.05B
Market cap186.05B
Price-Earnings ratio
26.64
Price-Earnings ratio26.64
Dividend yield
2.73%
Dividend yield2.73%
Average volume
2.87M
Average volume2.87M
High today
$346.00
High today$346.00
Low today
$342.29
Low today$342.29
Open price
$344.00
Open price$344.00
Volume
1.27M
Volume1.27M
52 Week high
$346.00
52 Week high$346.00
52 Week low
$253.30
52 Week low$253.30

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $342.36. The company's market cap stands at 186.05B, with a P/E ratio of 26.64 and a dividend yield of 2.7%.

On 2025-11-29, Amgen(AMGN) stock moved within a range of $342.29 to $346.00. With shares now at $342.36, the stock is trading +0.0% above its intraday low and -1.1% below the session's peak.

Trading activity shows a volume of 1.27M, compared to an average daily volume of 2.87M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $346.00 and a low of $253.30.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $346.00 and a low of $253.30.

AMGN News

Simply Wall St 2d
A Look at Amgen’s Valuation After Full FDA Approval for IMDELLTRA in Small Cell Lung Cancer

Amgen (AMGN) just secured full approval from the FDA for IMDELLTRA, its new therapy for adults with advanced small cell lung cancer that has progressed after pl...

A Look at Amgen’s Valuation After Full FDA Approval for IMDELLTRA in Small Cell Lung Cancer
Simply Wall St 3d
How FDA Approval and New Guidelines for IMDELLTRA Could Shape Amgen Investor Expectations

Amgen recently announced that the FDA granted full approval to IMDELLTRA (tarlatamab-dlle) for adults with extensive stage small cell lung cancer (ES-SCLC) whos...

How FDA Approval and New Guidelines for IMDELLTRA Could Shape Amgen Investor Expectations
Zacks 4d
Top Analyst Reports for NVIDIA, AT&T & Amgen

Tuesday, November 25, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research repor...

Top Analyst Reports for NVIDIA, AT&T & Amgen

Analyst ratings

45%

of 33 ratings
Buy
45.5%
Hold
45.5%
Sell
9.1%

More AMGN News

TipRanks 5d
Amgen assumed with a Hold at Truist

Truist assumed coverage of Amgen (AMGN) with a Hold rating with a price target of $318, up from $298. The firm views the stock as a defensive biotech with a sta...

TipRanks 7d
Teva, Amgen, Rithm, Fastly, Medtronic: Major Stock Moves!

Insiders have been trading these 5 stocks: ((TEVA)), ((AMGN)), ((RITM)), ((FSLY)) and ((MDT)). Here is a breakdown of their recent trades and their value. TipR...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.